

ABSTRACT

An object of the present invention is to provide a compound with an improved balance of S1P₅ receptor agonist activity with respect to S1P₁ receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P₅ receptor-
5 selective agonist activity on the S1P₁ receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.